Compare WHG & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | HUMA |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 182.6M |
| IPO Year | 2002 | N/A |
| Metric | WHG | HUMA |
|---|---|---|
| Price | $15.52 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 7.2K | ★ 5.9M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $97,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $731.05 |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.37 | $0.88 |
| 52 Week High | $18.99 | $3.35 |
| Indicator | WHG | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 58.71 |
| Support Level | $14.51 | $0.92 |
| Resistance Level | $15.70 | $1.26 |
| Average True Range (ATR) | 0.60 | 0.09 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 20.41 | 72.22 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.